Jamie Dwyer, MD
Nephrology · Nashville, TNNPI 1851303788
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $435,028 of the $460,613 with a category attached, or 94.4%. 22 manufacturers reported payments, led by AstraZeneca at 41.7% of the total. 2025 is the largest year on record at $155,238, 3.9 times the $40,242 reported in 2019. Among nephrology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $2476.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$192K
- Eli Lilly$83K
- CSL Behring$36K
- Astrazeneca UK Limited$30K
- Bayer$19K
- Ardelyx, Inc.$17K
- plus $84K from 16 others
Across 162 payments — averaging $733.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$87K
- AstraZeneca$32K
What the payments were for
- Consulting fees$435,02894%
- Speaking & faculty fees$8,5122%
- Travel & lodging$15,2173%
- Food & beverage$1,8570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 104 | $191,901 |
| Eli Lilly | 19 | $83,118 |
| CSL Behring | 13 | $36,313 |
| Astrazeneca UK Limited | 11 | $29,686 |
| Bayer | 10 | $19,026 |
| Ardelyx, Inc. | 2 | $16,500 |
| Ionis Pharmaceuticals, Inc. | 3 | $12,350 |
| Alnylam Pharmaceuticals Inc. | 1 | $11,600 |
| Travere Therapeutics, Inc. | 1 | $9,000 |
| Boehringer Ingelheim | 5 | $8,400 |
| GSK | 1 | $7,800 |
| Astrazeneca AB | 2 | $7,197 |
| Akcea Therapeutics, Inc. | 2 | $4,600 |
| Sanofi US Services Inc. | 1 | $4,230 |
| Akebia Therapeutics Inc | 1 | $3,480 |
| Ipsen Bioscience Inc. | 2 | $3,278 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,760 |
| Genentech, Inc. | 3 | $2,520 |
| Applied Therapeutics, Inc. | 1 | $2,400 |
| Sanofi | 1 | $1,831 |
| Bard Peripheral Vascular, Inc. | 1 | $1,800 |
| Lilly USA, LLC | 1 | $825 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$45,638
- LOKELMA$27,602
- TRYNGOLZA$12,350
- Kerendia$8,075
- JARDIANCE$6,325
- SAPHNELO$4,625
- SOTAGLIFLOZIN$4,230
- AURYXIA$3,480
- CRESTOR$1,945
- Non-Covered$1,842
How this compares
$460,613 in reported general payments places this provider in the 95th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 11 | $1,212 |
| Amlodipine Besylate | 11 | $142 |
| Lisinopril | 12 | $89 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Nashville
- Volker HaaseNashville$123K
- Talat IkizlerNashville$93K
- Julia LewisNashville$87K
- Osama El ShamyNashville$87K
- Thomas GolperNashville$26K
- Anthony LangoneNashville$23K
- James LutherNashville$20K
- Jeffrey HymesNashville$19K
- Roy ZentNashville$17K
- Alfred GeorgeNashville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.